Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451
Phase 3
- Conditions
- Hypertension, Dyslipidemia
- Interventions
- Drug: Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)Drug: Amlodipine/Olmesartan 10/40mg (Combination drug)
- Registration Number
- NCT04161001
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Brief Summary
* the change of sitSBP based on baseline between Treatment arm and control 1 arm \[ Time Frame: 8 weeks \]
* the change of LDL-C based on baseline between Treatment arm and control2 arm \[ Time Frame: 8 weeks \]
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 237
Inclusion Criteria
- Age 19 to 80 years
- patients with hypertension and hyperlipidemias
Exclusion Criteria
- orthostatic hypotension
- History of ventricular tachycardia, atrial fibrillation
- uncontrolled diabetes mellitus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Amlodpine, Olmesartan, Rosuvastatin, Ezetimibe Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug) co-administration of Olmesartan, Amlodipine and Rosuvastatin, Ezetimibe Amlodpine, Olmesartan Amlodipine/Olmesartan 10/40mg (Combination drug) co-administration of Olmesartan, Amlodipine Olmesartan, Rosuvastatin, Ezetimibe Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug) co-administration of Olmesartan and Rosuvastatin, Ezetimibe
- Primary Outcome Measures
Name Time Method the change of MSSBP based on baseline between Treatment arm and control 1 arm 8 weeks the change of LDL-C based on baseline between Treatment arm and control2 arm 8 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Yonsei University Health System, Severance Hospital
🇰🇷Seoul, Korea, Republic of